PFE · 8-K · 20260618PR000085

Management Changes

PFIZER INC · 2026-06-18 · Importance 31 · Surprise 42

Dave Denton will step down as Pfizer’s Chief Financial Officer and leave the company on August 15, 2026, for an external consumer-goods opportunity. Cecile Guegan, currently Senior Vice President of Finance for Pfizer’s Global Biopharmaceutical Business, will become Interim Chief Financial Officer on August 16, 2026. Guegan has more than 20 years of Pfizer experience and led finance for the biopharmaceutical business across therapeutic areas and geographies, including the 2024 integration of Seagen.

Key facts

• Cecile Guegan led the integration of Seagen into Pfizer in 2024. source
• Pfizer announced the information in this release is as of June 18, 2026. source
• Pfizer stated Dave Denton served as a steward of Pfizer’s financial health and led during business transactions including Seagen, Biohaven, and Metsera. source
• Cecile Guegan is currently Senior Vice President, Finance, Global Biopharmaceutical Business at Pfizer. source
• Cecile Guegan has more than two decades of experience at Pfizer. source
• In her current role, Cecile Guegan is directly responsible for the financial operations and reporting of Pfizer’s biopharmaceutical business across all therapeutic areas and geographies. source
• Cecile Guegan holds a Master in Business degree from Brest Business School. source